ModernMedicine Resource Center More Topics
 

Advances in moderate-to-severe Atopic Dermatitis

New therapeutic optionLong-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
Center’s goal: Give skin disease researchers all they needA new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Phase 3 results demonstrate dupilumab efficacyNew data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Appreciating the role of microbial communities on the skinMicrobial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
Pattern distinguishes atopic, contact dermatitisPart of the management of contact dermatitis is identifying the offending agent through patch testing and eliminating contact with the offending agent.
Investigative eczema drug shows positive phase 2 resultsUK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Merger to boost eczema offeringsPfizer and Anacor Pharmaceuticals announced in May that the pharmaceutical companies merged with Pfizer acquiring Anacor for about $5.2 billion. Dermatologists say merger is a good move for patients.
Oatmeal soothes, relieves, and inhibits viruses
Oatmeal soothes, relieves, and inhibits virusesGood for more than a morning meal, oatmeal soothes angry skin, relieves itching, and even has an antimicrobial effect.